JP2010533714A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010533714A5 JP2010533714A5 JP2010517010A JP2010517010A JP2010533714A5 JP 2010533714 A5 JP2010533714 A5 JP 2010533714A5 JP 2010517010 A JP2010517010 A JP 2010517010A JP 2010517010 A JP2010517010 A JP 2010517010A JP 2010533714 A5 JP2010533714 A5 JP 2010533714A5
- Authority
- JP
- Japan
- Prior art keywords
- picoplatin
- cancer
- formulation
- item
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims description 98
- 229950005566 picoplatin Drugs 0.000 claims description 98
- 239000000203 mixture Substances 0.000 claims description 81
- 238000009472 formulation Methods 0.000 claims description 76
- 238000000034 method Methods 0.000 claims description 56
- 239000002105 nanoparticle Substances 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 229920001223 polyethylene glycol Polymers 0.000 claims description 25
- 201000011510 cancer Diseases 0.000 claims description 24
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 22
- 239000000787 lecithin Substances 0.000 claims description 22
- 235000010445 lecithin Nutrition 0.000 claims description 22
- 229940067606 lecithin Drugs 0.000 claims description 22
- 239000011159 matrix material Substances 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 19
- 239000002609 medium Substances 0.000 claims description 17
- 239000003921 oil Substances 0.000 claims description 16
- 235000019198 oils Nutrition 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000002202 Polyethylene glycol Substances 0.000 claims description 14
- 239000000725 suspension Substances 0.000 claims description 14
- 150000002194 fatty esters Chemical class 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 12
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 11
- 239000007962 solid dispersion Substances 0.000 claims description 11
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 10
- 239000006185 dispersion Substances 0.000 claims description 10
- 102000011632 Caseins Human genes 0.000 claims description 9
- 108010076119 Caseins Proteins 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 206010014733 Endometrial cancer Diseases 0.000 claims description 8
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 8
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 8
- 206010038389 Renal cancer Diseases 0.000 claims description 8
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 8
- 239000003995 emulsifying agent Substances 0.000 claims description 8
- 230000002496 gastric effect Effects 0.000 claims description 8
- 201000010982 kidney cancer Diseases 0.000 claims description 8
- 239000000155 melt Substances 0.000 claims description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
- 239000005018 casein Substances 0.000 claims description 7
- 235000021240 caseins Nutrition 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims description 6
- 150000002334 glycols Chemical class 0.000 claims description 6
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 6
- 229960004679 doxorubicin Drugs 0.000 claims description 5
- 229940043355 kinase inhibitor Drugs 0.000 claims description 5
- 230000005855 radiation Effects 0.000 claims description 5
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 4
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 4
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 206010027406 Mesothelioma Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 229940123237 Taxane Drugs 0.000 claims description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 208000000728 Thymus Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 4
- 229940100198 alkylating agent Drugs 0.000 claims description 4
- 239000002168 alkylating agent Substances 0.000 claims description 4
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 4
- 230000000340 anti-metabolite Effects 0.000 claims description 4
- 229940100197 antimetabolite Drugs 0.000 claims description 4
- 239000002256 antimetabolite Substances 0.000 claims description 4
- 239000000010 aprotic solvent Substances 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 208000002458 carcinoid tumor Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 208000014761 nasopharyngeal type undifferentiated carcinoma Diseases 0.000 claims description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical class COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000003909 protein kinase inhibitor Substances 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 claims description 3
- 235000019483 Peanut oil Nutrition 0.000 claims description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 3
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 claims description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 3
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- 230000022131 cell cycle Effects 0.000 claims description 3
- 230000032823 cell division Effects 0.000 claims description 3
- 235000012343 cottonseed oil Nutrition 0.000 claims description 3
- 239000002385 cottonseed oil Substances 0.000 claims description 3
- 239000008157 edible vegetable oil Substances 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 239000011859 microparticle Substances 0.000 claims description 3
- 239000000312 peanut oil Substances 0.000 claims description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 229950008882 polysorbate Drugs 0.000 claims description 3
- 239000003549 soybean oil Substances 0.000 claims description 3
- 235000012424 soybean oil Nutrition 0.000 claims description 3
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 claims description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 2
- 239000012736 aqueous medium Substances 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 229940071162 caseinate Drugs 0.000 claims description 2
- 229960005395 cetuximab Drugs 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 2
- 229960001433 erlotinib Drugs 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 239000012943 hotmelt Substances 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 229960002446 octanoic acid Drugs 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 229920001993 poloxamer 188 Polymers 0.000 claims description 2
- 229940044519 poloxamer 188 Drugs 0.000 claims description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 claims description 2
- 229940080237 sodium caseinate Drugs 0.000 claims description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 2
- 229960001796 sunitinib Drugs 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 229960000303 topotecan Drugs 0.000 claims description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- 229960002066 vinorelbine Drugs 0.000 claims description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229960002550 amrubicin Drugs 0.000 claims 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 claims 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 1
- YMNCVRSYJBNGLD-KURKYZTESA-N cephalotaxine Chemical class C([C@@]12C=C([C@H]([C@H]2C2=C3)O)OC)CCN1CCC2=CC1=C3OCO1 YMNCVRSYJBNGLD-KURKYZTESA-N 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 229940115080 doxil Drugs 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000005457 triglyceride group Chemical group 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- DSRNKUZOWRFQFO-UHFFFAOYSA-N cephalotaxine Natural products COC1=CC23CCCN2CCc4cc5OCOc5cc4C3=C1O DSRNKUZOWRFQFO-UHFFFAOYSA-N 0.000 description 3
- 208000026037 malignant tumor of neck Diseases 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical group OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- 206010007275 Carcinoid tumour Diseases 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- -1 i.e. Chemical compound 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95003307P | 2007-07-16 | 2007-07-16 | |
| US4396208P | 2008-04-10 | 2008-04-10 | |
| PCT/US2008/008669 WO2009011861A1 (en) | 2007-07-16 | 2008-07-16 | Oral formulations for picoplatin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010533714A JP2010533714A (ja) | 2010-10-28 |
| JP2010533714A5 true JP2010533714A5 (OSRAM) | 2012-09-20 |
Family
ID=40259929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010517010A Withdrawn JP2010533714A (ja) | 2007-07-16 | 2008-07-16 | ピコプラチンのための経口製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100310661A1 (OSRAM) |
| EP (1) | EP2178893A4 (OSRAM) |
| JP (1) | JP2010533714A (OSRAM) |
| CN (1) | CN101809024A (OSRAM) |
| CA (1) | CA2693057A1 (OSRAM) |
| TW (1) | TW200920347A (OSRAM) |
| WO (1) | WO2009011861A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168661B2 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| CN101663040A (zh) * | 2007-02-09 | 2010-03-03 | 帕纳德制药公司 | 包封的吡铂 |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| CN102006875A (zh) * | 2008-02-08 | 2011-04-06 | 帕纳德制药公司 | 吡铂和贝伐单抗治疗结直肠癌的用途 |
| EP2418955A4 (en) * | 2009-04-15 | 2012-11-21 | Poniard Pharmaceuticals Inc | ORBIOTIC ANTICANCER THERAPY BASED ON HIGH BIODISIBILITY PICOPLATIN |
| CN102665689B (zh) * | 2009-09-21 | 2015-04-22 | Jw制药公司 | 奥沙利铂纳米颗粒及其制备方法 |
| BR112012030654B1 (pt) * | 2010-06-02 | 2021-11-09 | Astellas Deutschland Gmbh | Composição farmacêutica para administração oral compreendendo bendamustina ou um sal farmaceuticamente aceitável da mesma, como um ingrediente ativo, e um excipiente farmaceuticamente aceitável |
| CN101926757B (zh) * | 2010-09-01 | 2013-01-02 | 北京大学 | 一种难溶性药物的液体组合物及其制备方法 |
| US9381518B2 (en) | 2011-10-31 | 2016-07-05 | Merck Sharp & Dohme Corp. | Nano-suspension process |
| US9849088B2 (en) | 2012-05-10 | 2017-12-26 | Painreform Ltd. | Depot formulations of a hydrophobic active ingredient and methods for preparation thereof |
| ES2895948T3 (es) | 2015-07-30 | 2022-02-23 | Dae Hwa Pharma Co Ltd | Composición farmacéutica para administración oral que comprende taxano a alta concentración |
| KR101612257B1 (ko) | 2015-07-30 | 2016-04-20 | 대화제약 주식회사 | 고농도의 탁산을 포함하는 경구 투여용 약학 조성물 |
| KR101612260B1 (ko) | 2015-07-30 | 2016-04-20 | 대화제약 주식회사 | 고농도의 탁산을 포함하는 경구 투여용 약학 조성물 |
| GB2541387A (en) * | 2015-08-14 | 2017-02-22 | Res Center Pharmaceutical Eng Gmbh | Self-emulsifying Nanosuspensions as Drug Delivery Systems (SENDDS) |
| GB2561497B (en) * | 2015-12-08 | 2020-06-24 | Bluelight Pharmatech Co Ltd | A process for preparing a solid dispersion of decoquinate |
| US11571385B2 (en) | 2017-05-18 | 2023-02-07 | Kewpie Corporation | Self-emulsifiable composition, production method therefor, nanoemulsion, and production method therefor |
| CN108066771A (zh) * | 2017-12-15 | 2018-05-25 | 北京思如诺科技有限公司 | 一种具有高载药量环境响应型抗肿瘤纳米药物、载体以及制备方法 |
| PL247245B1 (pl) * | 2019-01-31 | 2025-06-02 | Gdanski Univ Medyczny | Samoemulgująca kompozycja farmaceutyczna w postaci ciekłej zawierająca jako substancję aktywną substancję leczniczą nietrwałą w środowisku wodnym |
| GB2622741A (en) * | 2022-07-06 | 2024-03-27 | Avantsar Sdn Bhd | A self-emulsifying drug delivery formulation with improved oral bioavailability of lipophilic compound |
| CN119699569B (zh) * | 2024-12-23 | 2025-10-17 | 晨光生物科技集团股份有限公司 | 一种叶黄素酯油悬液及其制备方法与应用 |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US623782A (en) * | 1899-04-25 | Filtering-intake | ||
| GB1432562A (en) * | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum co-ordination compounds |
| US4329299A (en) * | 1979-08-23 | 1982-05-11 | Johnson, Matthey & Co., Limited | Composition of matter containing platinum |
| US4302446A (en) * | 1979-10-02 | 1981-11-24 | Bristol-Myers Company | Pharmaceutical compositions |
| GR75317B (OSRAM) * | 1980-09-03 | 1984-07-13 | Johnson Matthey Plc | |
| US4533502A (en) * | 1983-02-22 | 1985-08-06 | Rochon Fernande D | Platinum (II) compounds and their preparation |
| DE3582961D1 (de) * | 1984-06-27 | 1991-07-04 | Johnson Matthey Plc | Platinkoordinationsverbindungen. |
| US5082655A (en) * | 1984-07-23 | 1992-01-21 | Zetachron, Inc. | Pharmaceutical composition for drugs subject to supercooling |
| US4902797A (en) * | 1986-12-18 | 1990-02-20 | Shionogi & Co., Ltd. | Ammine-alicyclic amine-platinum complexes and antitumor agents |
| GB9105037D0 (en) * | 1991-03-09 | 1991-04-24 | Johnson Matthey Plc | Improvements in chemical compounds |
| US5244991A (en) * | 1991-10-15 | 1993-09-14 | Phillips Petroleum Company | Olefin polymerization process |
| ES2204894T3 (es) * | 1991-11-15 | 2004-05-01 | Smithkline Beecham Corporation | Composicion que contiene cisplatino y topotecan como agente antitumoral. |
| JP3633932B2 (ja) * | 1992-04-01 | 2005-03-30 | ザ ジョーンズ ホプキンズ ユニバーシティー スクール オブ メディシン | 糞便試料から単離した哺乳類の核酸を検出する方法、およびその検出用試薬 |
| US5624919A (en) * | 1993-09-14 | 1997-04-29 | The University Of Vermont And State Agricultural College | Trans platinum (IV) complexes |
| GB9408218D0 (en) * | 1994-04-26 | 1994-06-15 | Johnson Matthey Plc | Improvements in platinum complexes |
| WO1996001638A1 (en) * | 1994-07-11 | 1996-01-25 | Hoechst Marion Roussel, Inc. | Method of treating a neoplastic disease state by conjunctive therapy with 2'-fluoromethylidene derivatives and radiation or chemotherapy |
| US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| GB9502799D0 (en) * | 1995-02-14 | 1995-04-05 | Johnson Matthey Plc | Improvements in platinum complexes |
| US5798589A (en) * | 1995-09-13 | 1998-08-25 | Zexel Corporation | Brushless motor having lubrication system for upper and lower bearings |
| US6245349B1 (en) * | 1996-02-23 | 2001-06-12 | éLAN CORPORATION PLC | Drug delivery compositions suitable for intravenous injection |
| US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
| US5919815A (en) * | 1996-05-22 | 1999-07-06 | Neuromedica, Inc. | Taxane compounds and compositions |
| JP2000515852A (ja) * | 1996-06-25 | 2000-11-28 | グラクソ、グループ、リミテッド | Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、ｆｔｃおよび／または３ｔｃを含んでなる組合わせ |
| US5976577A (en) * | 1997-07-11 | 1999-11-02 | Rp Scherer Corporation | Process for preparing fast dispersing solid oral dosage form |
| US20030059465A1 (en) * | 1998-05-11 | 2003-03-27 | Unger Evan C. | Stabilized nanoparticle formulations of camptotheca derivatives |
| DE19847618A1 (de) * | 1998-10-15 | 2000-04-20 | Basf Ag | Verfahren zur Herstellung von festen Dosierungsformen |
| US20020054914A1 (en) * | 1999-02-03 | 2002-05-09 | Tulin Morcol | Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein |
| JP4756669B2 (ja) * | 1999-04-13 | 2011-08-24 | アノーメッド・インコーポレイテッド | アミン白金錯体を調製するためのプロセス |
| US6413953B1 (en) * | 1999-04-13 | 2002-07-02 | Anormed Inc. | Pt(IV) antitumor agent |
| GB9925127D0 (en) * | 1999-10-22 | 1999-12-22 | Pharmacia & Upjohn Spa | Oral formulations for anti-tumor compounds |
| US20020102301A1 (en) * | 2000-01-13 | 2002-08-01 | Joseph Schwarz | Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof |
| EP1256344B1 (en) * | 2000-02-16 | 2006-12-20 | Astellas Pharma Inc. | Remedies for endothelin-induced diseases |
| EP1261356A2 (en) * | 2000-02-29 | 2002-12-04 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with platinum compounds |
| US20020156033A1 (en) * | 2000-03-03 | 2002-10-24 | Bratzler Robert L. | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
| US6545010B2 (en) * | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
| US20020110601A1 (en) * | 2000-03-31 | 2002-08-15 | Roman Perez-Soler | Antineoplastic platinum therapeutic method and composition |
| EE200200565A (et) * | 2000-03-31 | 2004-06-15 | Angiogene Pharmaceuticals Ltd. | Vaskulaarse kahjustava toimega kombinatsioonravi |
| GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| CA2410683A1 (en) * | 2000-07-24 | 2002-01-31 | Pharmacia & Upjohn Company | Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs |
| WO2002013817A1 (en) * | 2000-08-11 | 2002-02-21 | Sumitomo Pharmaceuticals Co., Ltd. | Remedies for cisplatin-tolerant cancer |
| US6894049B1 (en) * | 2000-10-04 | 2005-05-17 | Anormed, Inc. | Platinum complexes as antitumor agents |
| CA2326004A1 (en) * | 2000-11-02 | 2002-05-02 | Richard E. Jones | Methods for treating cellular proliferative disorders |
| SE0004671D0 (sv) * | 2000-12-15 | 2000-12-15 | Amarin Dev Ab | Pharmaceutical formulation |
| US6673370B2 (en) * | 2001-05-15 | 2004-01-06 | Biomedicines, Inc. | Oxidized collagen formulations for use with non-compatible pharmaceutical agents |
| IL160103A0 (en) * | 2001-08-06 | 2004-06-20 | Astrazeneca Ab | Aqueous dispersion comprising stable nanoparticles of a water-insoluble active substance and an excipient like middle chain triglycerides (mct) |
| US20030059375A1 (en) * | 2001-08-20 | 2003-03-27 | Transave, Inc. | Method for treating lung cancers |
| DE10141528B4 (de) * | 2001-08-24 | 2006-08-10 | Faustus Forschungs Cie. Translational Cancer Research Gmbh | Platin(II)- und Platin(IV)-Komplexe und ihre Verwendung |
| US20030144312A1 (en) * | 2001-10-30 | 2003-07-31 | Schoenhard Grant L. | Inhibitors of ABC drug transporters in multidrug resistant cancer cells |
| US20060078618A1 (en) * | 2001-12-11 | 2006-04-13 | Constantinides Panayiotis P | Lipid particles and suspensions and uses thereof |
| IL163808A0 (en) * | 2002-03-01 | 2005-12-18 | Yissum Res Dev Co | Self emulsifying drug delivery systems for poorly soluble drugs |
| US7691833B2 (en) * | 2002-03-01 | 2010-04-06 | Trustees Of Dartmouth College | Compositions and methods for preventing sporadic neoplasia in colon |
| US20040010553A1 (en) * | 2002-07-15 | 2004-01-15 | International Business Machines Corporation | Peer to peer location based services |
| AU2003251955A1 (en) * | 2002-07-16 | 2004-02-02 | Sonus Pharmaceuticals, Inc. | Platinum compound |
| JP2006502233A (ja) * | 2002-08-02 | 2006-01-19 | トランセーブ，インク． | 白金凝集物およびその製造方法 |
| AU2003258075A1 (en) * | 2002-08-06 | 2004-02-23 | Lyotropic Therapeutics, Inc. | Lipid-drug complexes in reversed liquid and liquid crystalline phases |
| AU2002951833A0 (en) * | 2002-10-02 | 2002-10-24 | Novogen Research Pty Ltd | Compositions and therapeutic methods invloving platinum complexes |
| US8217010B2 (en) * | 2002-10-24 | 2012-07-10 | The Board Of Trustees Of The University Of Illinois | Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
| TWI323662B (en) * | 2002-11-15 | 2010-04-21 | Telik Inc | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
| DE10256182A1 (de) * | 2002-12-02 | 2004-06-24 | Merck Patent Gmbh | 2-Oxadiazolchromonderivate |
| DE502004006542D1 (de) * | 2003-04-30 | 2008-04-30 | Merck Patent Gmbh | Chromenonderivate |
| US20050020556A1 (en) * | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes |
| US20070065522A1 (en) * | 2004-03-18 | 2007-03-22 | Transave, Inc. | Administration of high potency platinum compound formulations by inhalation |
| WO2005111024A1 (en) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| CA2564199A1 (en) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| TW200538149A (en) * | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
| TW200600091A (en) * | 2004-05-21 | 2006-01-01 | Telik Inc | Sulfonylethyl phosphorodiamidates |
| US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| EP2027853A3 (en) * | 2004-06-18 | 2011-01-05 | Agennix USA Inc. | Kinase inhibitors for treating cancers |
| US20060003950A1 (en) * | 2004-06-30 | 2006-01-05 | Bone Care International, Inc. | Method of treating prostatic diseases using a combination of vitamin D analogues and other agents |
| US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| RU2361592C2 (ru) * | 2004-09-22 | 2009-07-20 | Пфайзер Инк. | Терапевтические комбинации, содержащие ингибитор поли(адф-рибоза)полимеразы |
| US20060205810A1 (en) * | 2004-11-24 | 2006-09-14 | Schering Corporation | Platinum therapeutic combinations |
| WO2006071812A2 (en) * | 2004-12-23 | 2006-07-06 | H. Lee Moffitt Cancer Center And Research Institute | Platinum iv complex inhibitor |
| WO2006090931A1 (ja) * | 2005-02-28 | 2006-08-31 | Eisai R & D Management Co., Ltd. | スルホンアミド化合物の抗癌剤との新規併用 |
| US8106033B2 (en) * | 2005-03-11 | 2012-01-31 | Temple University - Of The Commonwealth System Of Higher Education | Composition and methods for the treatment of proliferative diseases |
| KR101533268B1 (ko) * | 2005-05-12 | 2015-07-03 | 애브비 바하마스 리미티드 | 아폽토시스 촉진제 |
| AU2006284657B2 (en) * | 2005-08-31 | 2012-07-19 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| WO2007056264A2 (en) * | 2005-11-08 | 2007-05-18 | Transave, Inc. | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
| WO2007056236A2 (en) * | 2005-11-08 | 2007-05-18 | Transave, Inc. | Methods of treating cancer with lipid-based platinum compound formulations administered intravenously |
| US20070190180A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| WO2007064658A2 (en) * | 2005-11-30 | 2007-06-07 | Transave, Inc. | Safe and effective methods of administering therapeutic agents |
| US8143236B2 (en) * | 2005-12-13 | 2012-03-27 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods |
| EP3231442B1 (en) * | 2006-06-23 | 2019-12-25 | ADC Therapeutics SA | Polynucleotides and polypeptide sequences involved in cancer |
| US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| CN101663040A (zh) * | 2007-02-09 | 2010-03-03 | 帕纳德制药公司 | 包封的吡铂 |
| JP2010529023A (ja) * | 2007-05-31 | 2010-08-26 | アセンタ セラピューティックス インコーポレイティッド | 疾患の処置のためのゴシポールの律動的投薬法 |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| ES2647538T3 (es) * | 2007-09-28 | 2017-12-22 | Pfizer Inc. | Direccionamiento a células de cáncer usando nanopartículas |
| CN102006875A (zh) * | 2008-02-08 | 2011-04-06 | 帕纳德制药公司 | 吡铂和贝伐单抗治疗结直肠癌的用途 |
-
2008
- 2008-07-16 US US12/669,274 patent/US20100310661A1/en not_active Abandoned
- 2008-07-16 EP EP08780206A patent/EP2178893A4/en not_active Withdrawn
- 2008-07-16 CN CN200880103323A patent/CN101809024A/zh active Pending
- 2008-07-16 WO PCT/US2008/008669 patent/WO2009011861A1/en not_active Ceased
- 2008-07-16 JP JP2010517010A patent/JP2010533714A/ja not_active Withdrawn
- 2008-07-16 TW TW097127053A patent/TW200920347A/zh unknown
- 2008-07-16 CA CA 2693057 patent/CA2693057A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010533714A5 (OSRAM) | ||
| KR100904931B1 (ko) | 나노 입자 및 그의 제조 방법 | |
| TWI417114B (zh) | 具有增強穩定性之弱水溶性藥物之組合物及其製備方法 | |
| KR102203555B1 (ko) | 입자의 동결건조 또는 동결을 위한 중합체 부형제의 용도 | |
| JP2010533714A (ja) | ピコプラチンのための経口製剤 | |
| Kumar et al. | Novel approaches for enhancement of drug bioavailability | |
| Garg et al. | Colloidal drug delivery systems: current status and future directions | |
| WO2010045292A2 (en) | Nanoparticle compositions comprising liquid oil cores | |
| CN102370622A (zh) | 一种载药物纳米粒及其制备方法和应用 | |
| CN108567742B (zh) | Sn38脂质组合物、其制备方法和用途 | |
| TWI880897B (zh) | 腫瘤內注射調配物 | |
| CN102357075A (zh) | 一种多西他赛纳米制剂及其制备方法 | |
| JP5759464B2 (ja) | オキサリプラチンのナノ粒子及びその製造方法 | |
| TW201705941A (zh) | 經磷脂塗覆的治療劑奈米粒子及其相關方法 | |
| Drais et al. | Investigation of lipid polymer hybrid nanocarriers for oral felodipine delivery: Formulation, method, in-vitro and ex-vivo evaluation | |
| Cheng et al. | Carfilzomib and paclitaxel co-loaded protein nanoparticles an effective therapy against pancreatic adenocarcinomas | |
| Chakraborty et al. | A critical appraisal of lipid nanoparticles deployed in cancer pharmacotherapy | |
| KR101180181B1 (ko) | 나노 입자 및 그의 제조 방법 | |
| Nayak et al. | Advanced and Modern Approaches for Drug Delivery | |
| WO2017214468A1 (en) | Nanodroplet compositions for the efficient delivery of anti-cancer agents | |
| I Jethara et al. | Recent patents survey on self emulsifying drug delivery system | |
| Margaret et al. | LIPID NANOCARRIERS FOR TARGETING ORAL CANCER: AN UPDATED REVIEW | |
| JP4877899B2 (ja) | 薬物徐放出性球状微粒子及びその製造方法 | |
| CN102772369A (zh) | 一种多烯紫杉醇长循环纳米粒制剂及其制备方法 | |
| CN101703462A (zh) | 冬凌草乙素高度分散制剂 |